Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach
Victória Etges Helfer(University of North Carolina at Chapel Hill), Valentina Shakhnovich(Ironwood Pharmaceuticals (United States)), Tyler Dunlap(University of North Carolina at Chapel Hill), Kathryn E. Kyler(Children's Mercy Hospital), Jansynn Radford(Smithsonian Marine Station), Anjana Sasidharan(Children's Mercy Hospital), Paul Toren(Children's Mercy Hospital), Rangaraj Selvarangan(Children's Mercy Hospital), Nathan S. Artz(Children's Mercy Hospital), Daniel González(University of North Carolina at Chapel Hill), Veronica Williams(Nemours Children's Clinic), Kim Gibson(Children's Mercy Hospital), Brandon Retke(Children's Mercy Hospital), Sherwin S. Chan(Children's Mercy Hospital)
Cited by 1
Related Papers
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
|Clinical Infectious Diseases|2020|232
Genotype Prevalence and Risk Factors for Severe Clinical Adenovirus Infection, United States 2004-2006
|Clinical Infectious Diseases|2007|226
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
|Obesity|2021|199
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
|Clinical Therapeutics|2016|170